Lanean...
Cardioprotective Properties of Omecamtiv Mecarbil against Ischemia and Reperfusion Injury
Omecamtiv mecarbil (OM) is a first-in-class myosin activator. It was developed as a new inotropic therapy option for heart failure and is currently the object of a phase 3 clinical trial program. OM activates ryanodine receptors, which were shown to be involved in cardioprotection induced by conditi...
Gorde:
| Argitaratua izan da: | J Clin Med |
|---|---|
| Egile Nagusiak: | , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6463149/ https://ncbi.nlm.nih.gov/pubmed/30889854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8030375 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|